Cipher Gene Snags ￥10M in Pre-B Round of Financing

According to VCBeat, Cipher Gene announced the closure of its Pre-B round of tens of millions, led by Chengshu Capital, with participation from Shengwan Investment and venture with Everest VC. Proceeds from the latest round will mainly be used in new product R&D, market expansion and team construction to speed up the development of Cipher Gene in the field of genetic disorders and rare diseases in children.

Established in October 2015, Cipher Gene is an innovative company dedicated to building a data-driven platform for the precise diagnosis and treatment of children's genetic diseases. 

With the completion of this round, the company will further consolidate its core advantages in the business of genetic disease diagnosis in children and plans to launch the CRO service system of drugs to further complete the company's strategic layout in the integration of diagnosis and treatment. The company will launch a series of products and services including iWES (the enhanced whole-exome sequencing for genetic diseases) based on second-generation sequencing, WGS (whole-genome sequencing) CRO service, high-throughput functional verification service and drug screening platform driven by genetic data.

Since 2016, when Cipher Gene fully focused on the field of childhood genetic diseases, the company has been well known in the industry for its whole-exome sequencing. The company uses the whole whole-exome sequencing technology to assist doctors in the accurate diagnosis of hereditary neurological disorders in children such as epilepsy. At present, it has also extended the indications for sequencing to the field of genetic or rare diseases in children.

Cipher Gene has established stable cooperation with nearly 300 medical and scientific research institutions, such as The First Hospital of Peking University, Xiangya Hospital of Central South University, Children's Hospital of Medical College of Zhejiang University, and so on.

Founded in 2010, the core team of Chengshu Investment has extensive contacts and resources in both the healthcare industry and the capital market. More than 10 enterprises in its portfolios have completed IPO in the A-share market. Chengshu Investment now focuses on the growth investment in the field of health care.

Guozhong Venture Capital was founded on the 21st of December 2015, currently being entrusted to manage the first entity fund of Small Medium Enterprises Development Fund（SHENZHEN）LLP with a size of 6 Billion yuan.

Guozhong Venture Capital has a registered size of 100million yuan, partners consisting of Shenzhen venture capital group (49%) and the management team of Small Medium Enterprise Development Fund (SHENZHEN) (51%).